Data Sciences International, a subsidiary of Harvard Bioscience, recently launched a new inhalation and exposure system called the DSI Buxco Inhalation Exposure System.
The new inhalation exposure system is designed for ease-of-use for researchers while also giving them flexibility. It features remote sensors and hardware control system that are linked by a microprocessor-based feedback loop. The system allows for a high degree of protocol repeatability which means high yield exposure studies with a reduced level of manual oversight. Researchers can perform real-time respiration monitoring during exposure by using FinePointe software.
“Delivering drugs to the lungs is gaining popularity for a variety of systemic diseases,” Jeffrey Duchemin, president and CEO of Harvard Bioscience, said. “Our expertise in respiratory instrumentation technology uniquely positions us in this rapidly growing market.”
Data Sciences International’s Buxco Inhalation Exposure System will help pharmaceutical companies develop drugs that are delivered through inhalation instead of the traditional ingestion method. According to the company, the market for inhalation drugs for respiratory and systemic diseases is about $48 billion.
